Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
How similar are metastases to the primary tumour and other metastases in the same patient? And what does that tell us about the evolution of metastatic ability? Two papers investigated these questions in pancreatic ductal adenocarcinoma (PDAC).
Estevaet al. have developed an artificial intelligence algorithm which recognises and classifies skin cancers as accurately as specialist clinicians, thereby automating diagnosis.
Sheltzeret al. find that single-chromosome gains can prevent tumorigenesis relative to genetically matched euploid cells, but that these aneuploid cells can evolve over time to have improved fitness.
Two papers demonstrate that centrosome amplification can cause cancer in mammals and that a PIDDosome–p53-dependent control mechanism acts to prevent cell proliferation in the presence of extra centrosomes.
In this Review, Nowell and Radtke outline the accumulating evidence that Notch functions as a tumour suppressor in a range of cancers, and present potential mechanisms by which loss of Notch signalling could promote tumorigenesis.
This review summarizes the state of the art in chemical probes targeting molecular processes operating at the chromatin interface in cancer cells. It seeks to provide a chemical toolbox for use by scientists to dissect epigenetic vulnerabilities of tumour biology.
Sumoylation is an important mechanism in cellular responses to stress, and appears to be upregulated in many cancers. This Review argues that sumoylation protects the stability and functionality of otherwise easily misregulated gene expression programmes and signalling pathways of cancer cells.
This Opinion article focuses on the trends and progress being made in identifying protein biomarker signatures of clinical utility in cancer using, in particular, blood-based proteomics.
